Radient, Grifols Enter Into Marketing, Distribution Agreement

Radient Pharmaceuticals, through its wholly-owned subsidiary, AMDL Diagnostics, has entered into an exclusive five-year marketing and distribution agreement with Grifols USA, a healthcare products manufacturer and distributor.

Under the terms of the agreement, Grifols will market and sell ADI’s DR-70 Onko-Sure cancer test for the monitoring of colorectal cancer (CRC) to hospitals, clinical labs, clinics, and other healthcare organizations throughout the US.

According to the terms, Grifols has the rights to market and distribute ADI’s Onko-Sure cancer test specifically for the monitoring of colorectal cancer in the US. This includes developing and implementing a marketing strategy to drive product awareness, educate clinical laboratories and physicians, and generate product sales.

Patricia Silver, general manager of US diagnostic division at Grifols, said: “We are intensely dedicated to providing hospitals, labs and clinics with highly innovative and in-demand products and services which improve the level and quality of patient health care around the world, and we are very pleased to support the commercialization of ADI’s Onko-Sure cancer test in the US.”

Douglas MacLellan, chairman and CEO of Radient Pharmaceuticals & ADI, said: “We are extremely pleased to announce a top-tier distribution partnership for our Onko-Sure cancer test in the USA. We are making great progress on our commercialization plan for Onko-Sure, and with this latest agreement, doing so with one of the most recognized, respected and experienced companies in the healthcare sector.

“We are dedicated to establishing a strong, long-lasting and highly successful relationship with the Grifols team one that will help make Onko-Sure the standard in cancer testing and deliver direct value to our customers, patients, and shareholders.”